by HTLV | Nov 2, 2022 | Publications
Front Immunol. 2022 Oct 10;13:991928. doi: 10.3389/fimmu.2022.991928. eCollection 2022. ABSTRACT Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus which mainly infects CD4+ T cells and causes adult T-cell leukemia/lymphoma (ATL), is primarily transmitted via...
by HTLV | Nov 2, 2022 | Publications
Front Immunol. 2022 Oct 13;13:954103. doi: 10.3389/fimmu.2022.954103. eCollection 2022. ABSTRACT HTLV-1-infected individuals may develop a neurologic inflammatory condition known as HTLV-1-associated myelopathy (HAM/TSP), in which the high production of TNF is...
by HTLV | Nov 2, 2022 | Publications
J Virol. 2022 Oct 31:e0133922. doi: 10.1128/jvi.01339-22. Online ahead of print. ABSTRACT Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)....
by | Nov 2, 2022 | Publications
Antioxidants (Basel). 2022 Oct 18;11(10):2054. doi: 10.3390/antiox11102054. ABSTRACT Most viruses encode their own proteases to carry out viral maturation and these often require dimerization for activity. Studies on human immunodeficiency virus type 1 (HIV-1), type 2...
by | Nov 2, 2022 | Publications
Bioengineering (Basel). 2022 Oct 6;9(10):527. doi: 10.3390/bioengineering9100527. ABSTRACT Previous studies have reported a close correlation between vascular endothelial growth factor (VEGF), which plays an important role in angiogenesis, and human T-cell leukemia...
by | Nov 2, 2022 | Publications
Cancer Med J. 2023;6(1):30-36. Epub 2022 Sep 13. ABSTRACT Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm with poor prognosis that can present as HTLV-1-associated bronchioloalveolar disease (HABA). Chemotherapy is recommended for ATL; however, it...